Current Report Filing (8-k)
May 10 2018 - 1:55PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 8,
2018
Creative Medical Technology Holdings,
Inc.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
000-53500
|
|
87-0622284
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
2017 W Peoria Avenue, Phoenix, AZ 85029
|
(Address of principal executive offices)
|
Registrant’s telephone number, including
area code:
(602) 680-7439
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
x
Emerging growth company If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
On May 8, 2018, Creative Medical Technology
Holdings, Inc., a Nevada corporation (the “
Company
”), issued two separate press releases, the first announcing
Dr. Alexander Gershman’s attendance at the American Urological Association conference to discuss the CaverStem
TM
Stem Cell Procedure for drug refractory erectile dysfunction, and the second announcing the filing of patent application number
62663912 covering the use of its AmnioStem
TM
stem cells as a means of reducing/reversing natural aging.
The press releases, furnished as Exhibits
99.1 and 99.2, respectively, to this Form 8-K, may contain forward-looking statements. Such forward-looking statements are based
on information presently available to the Company’s management and are current only as of the date made. Actual results could
also differ materially from those anticipated as a result of a number of factors, including, but not limited to, those discussed
in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, and subsequent reports filed by the Company
with the Securities and Exchange Commission (the “
Commission
”). For those reasons, undue reliance should not
be placed on any forward-looking statement. The Company assumes no duty or obligation to update or revise any forward-looking statement,
although it may do so from time to time as management believes is warranted or as may be required by applicable securities law.
Any such updates or revisions may be made by the registrant by filing reports with the Commission, through the issuance of press
releases or by other methods of public disclosure.
|
Item 9.01.
|
Financial Statements and Exhibits
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Creative Medical Technology Holdings, Inc.
|
|
|
|
|
|
|
|
Date: May 10, 2018
|
By:
|
/s/ Donald Dickerson
|
|
|
|
Donald Dickerson, Chief Financial Officer
|
|